Onko tämä taidetta? Taidekritiikki ja Tom palaa kotiin! -näyttelyn vastaanotto mediassa

Tutkielmassa tarkastellaan Tom of Finlandin alias Touko Laaksosen töitä esittelevän Tom palaa kotiin! -näyttelyn vastaanottoa mediassa. Näyttely oli osa Turun kulttuuripääkaupunkivuoden 2011 ohjelmistoa. Tom of Finlandin homoeroottisia töitä esittelevä näyttely herätti mediassa runsaasti huomiota ja näyttelyn soveltumista kulttuuripääkaupunkivuoden viralliseen ohjelmistoon arvosteltiin vilkkaasti lehdissä ja verkossa. Negatiivista kritiikkiä aiheuttivat erityisesti töiden eroottisuus sekä näyttelytilan avoimuus kulttuurikeskus Logomossa. Tutkielman teoriaosassa tarkastellaan perinteisen taidekritiikin nykytilaa sekä pohditaan sen suhdetta päivälehdissä julkaistaviin kulttuuriuutisiin. Lisäksi teoriaosassa pohditaan sosiaalisen median vaikutusta taiteesta käytävään keskusteluun sekä keskustelun diskurssikäytäntöjä. Analyysiosassa Tom of Finlandin näyttelyn saamaa julkisuutta lähestytään teoriaosassa esitettyjen huomioiden valossa. Tarkastelun kohteena on näyttelyn mediavastaanotto: tarkemmin ottaen sanoma- ja aikakausilehdissä julkaistut taidekritiikit ja -arviot sekä verkossa julkaistut mielipiteet ja uutiskommentit. Tom palaa kotiin! -näyttelyä koskevissa lehtikritiikeissä ja verkkokommenteissa painotettiin toistuvasti näyttelyn homoeroottista luonnetta. Varsinkin lehdissä julkaistuissa taidekritiikeissä keskityttiin itse taiteen analysoinnin sijaan taiteilijan biografiaan ja kulttuurihistorialliseen merkitykseen sekä tapahtuman yleiseen kuvailuun. Tutkimuksen päähypoteesi onkin, että perinteinen taidekritiikki on nykyisin varsin kritiikitöntä. Tutkimuksessa osoitetaan tapausesimerkin avulla, miten taiteesta nykyisin mediassa puhutaan.

Highlights from the I international symposium of thrombosis and anticoagulation in internal medicine, October 23-25, 2008, Sao Paulo, Brazil

The importance of thrombosis and anticoagulation in clinical practice is rooted firmly in several fundamental constructs that can be applied both broadly and globally. Awareness and the appropriate use of anticoagulant therapy remain the keys to prevention and treatment. However, to assure maximal efficacy and safety, the clinician must, according to the available evidence, choose the right drug, at the right dose, for the right patient, under the right indication, and for the right duration of time. The first International Symposium of Thrombosis and Anticoagulation in Internal Medicine was a scientific program developed by clinicians for clinicians. The primary objective of the meeting was to educate, motivate and inspire internists, cardiologists and hematologists by convening national and international visionaries, thought-leaders and dedicated clinician-scientists in Sao Paulo, Brazil. This article is a focused summary of the symposium proceedings. © Springer Science+Business Media, LLC 2009.

Resposta de celúlas odontoblastóides MDPC-23 irradiadas com LED de 630nm

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Oral live attenuated human rotavirus vaccine (RotarixTM) offers sustained high protection against severe G9P[8] rotavirus gastroenteritis during the first two years of life in Brazilian children

In a large Phase III trial conducted in 10 Latin American countries, the safety and efficacy of the live attenuated monovalent rotavirus vaccine RIX4414 was evaluated in 15,183 healthy infants followed up during the first two years of life. Belém was the only site in Brazil included in this multicentre trial. The study in Belém included a subset of 653 infants who were followed up until 24 months of age for protection against severe rotavirus gastroenteritis. These subjects were randomly assigned in a 1:1 ratio to receive two doses of vaccine (n = 328) or two doses of placebo (n = 325) at approximately two and four months of age. Of the 653 enrolled infants, 23 dropped out during the study period. For the combined two-year period, the efficacy of RIX4414 was 72.3% [95% confidence interval (CI) 37.5-89.1%] against severe rotavirus-related gastroenteritis, reaching a protection rate of 81.8% (95% CI 36.4-96.6%) against circulating wild-type G9 rotavirus strains. It is concluded that two doses of RIX4414 are highly efficacious against severe rotavirus gastroenteritis in Belém during the first two years of life and provide high protection against the worldwide emergence and spread of G9P[8] strains.

Biossorção do corante DR 23 por Saccharomyces cerevisiae imobilizada em serragem de peroba (Aspidosperma polyneuron) tratada com PEI (polietilenoimina)

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)

Duration of dual antiplatelet therapy and outcomes after coronary stenting with the genous (TM) bio-engineered R stent (TM) in patients from the e-healing registry

Objective: We investigated the relation between duration of dual antiplatelet therapy (DAPT) and clinical outcomes up to 12 months after Genous (TM) endothelial progenitor cell capturing R stent (TM) placement in patients from the e-HEALING registry. Background: Cessation of (DAPT) has been shown to be associated with the occurrence of stent thrombosis (ST). After Genous placement, 1 month of DAPT is recommended. Methods: Patients were analyzed according to continuation or discontinuation of DAPT at a 30-day and 6-month landmark, excluding patients with events before the landmark. Each landmark was a new baseline, and outcomes were followed up to 12 months after stenting. The main outcome for our current analysis was target vessel failure (TVF), defined as target vessel-related cardiac death or myocardial infarction and target vessel revascularization. Secondary outcomes included ST. (Un)adjusted hazard ratios (HR) for TVF were calculated with Cox regression. Results: No difference was observed in the incidence of TVF [HR: 1.03; 95% confidence intervals (CI): 0.651.65, P = 0.89] in patients continuing DAPT (n = 4,249) at 30 days versus patients stopped (n = 309), and HR: 0.82 (95% CI: 0.551.23, P = 0.34) in patients continuing DAPT (n = 2,654) at 6 months versus patients stopped [n = 1,408] DAPT). Furthermore, no differences were observed in ST. Even after addition of identified independent predictors for TVF, adjusted TVF hazards were comparable. Conclusions: In a post-hoc analysis of e-HEALING, duration of DAPT was not associated with the occurrence of the outcomes TVF or ST. The Genous stent may be an attractive treatment especially in patients at increased risk for (temporary) cessation of DAPT or bleeding. (C) 2011 Wiley Periodicals, Inc.